Open Access

Scutellarein suppresses Aβ‑induced memory impairment via inhibition of the NF‑κB pathway in vivo and in vitro

  • Authors:
    • Xiao‑Wei Huang
    • Yan Xu
    • Xin Sui
    • He Lin
    • Jia‑Ming Xu
    • Dong Han
    • Dou‑Dan Ye
    • Guang‑Fu Lv
    • Yue‑Xin Liu
    • Xiao‑Bo Qu
    • Ming‑Hua Duan
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/ol.2019.10274
  • Pages: 5581-5589
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The flavonoid compound scutellarin (Scu) is a traditional Chinese medicine used to treat a variety of diseases; however, the use of scutellarein (Scue), the hydrolysate of Scu, and its mechanisms of action in Alzheimer's disease (AD) have not been fully elucidated. In the present study, the effects of Scue on amyloid β (Aβ)‑induced AD‑like pathology were investigated. An in vitro model of inflammation and an aged rat model were used to confirm the effects of Scue. In vitro MTT assays and flow cytometry were used to assess the effects of Scue on cell viability and apoptosis, respectively. A Morris water maze was used to evaluate spatial learning and memory, and the levels of Aβ deposition, superoxide dismutase, malondialdehyde, apoptosis, neuro‑inflammatory factors and nuclear factor‑κB (NF‑κB) activation in hippocampal tissues in vivo were measured to determine the effect of Scue in AD. Scue may be protective, as it decreased the apoptosis of hippocampal cells in vitro, inhibited Aβ‑induced cognitive impairment, suppressed hippocampal neuro‑inflammation and suppressed activation of NF‑κB in vivo. Therefore, Scue may be a useful agent for the treatment of Aβ‑associated pathology in the central nervous system through inhibition of the protein kinase B/NF‑κB signaling pathway and thus, future studies are required to investigate the efficacy of Scue in patients with AD.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Huang, X., Xu, Y., Sui, X., Lin, H., Xu, J., Han, D. ... Duan, M. (2019). Scutellarein suppresses Aβ‑induced memory impairment via inhibition of the NF‑κB pathway in vivo and in vitro. Oncology Letters, 17, 5581-5589. https://doi.org/10.3892/ol.2019.10274
MLA
Huang, X., Xu, Y., Sui, X., Lin, H., Xu, J., Han, D., Ye, D., Lv, G., Liu, Y., Qu, X., Duan, M."Scutellarein suppresses Aβ‑induced memory impairment via inhibition of the NF‑κB pathway in vivo and in vitro". Oncology Letters 17.6 (2019): 5581-5589.
Chicago
Huang, X., Xu, Y., Sui, X., Lin, H., Xu, J., Han, D., Ye, D., Lv, G., Liu, Y., Qu, X., Duan, M."Scutellarein suppresses Aβ‑induced memory impairment via inhibition of the NF‑κB pathway in vivo and in vitro". Oncology Letters 17, no. 6 (2019): 5581-5589. https://doi.org/10.3892/ol.2019.10274